Hodgkins Lymphoma Market 2024: Opportunity Analysis and Forecasts
"The
Latest Research Report OpportunityAnalyzer: Hodgkins Lymphoma (HL) -
Opportunity Analysis and Forecasts to 2024 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
About
Hodgkins Lymphoma Market
Hodgkins lymphoma (HL), or
Hodgkins disease, is a malignancy which involves the lymph nodes and
the lymphatic system. HL is a relatively rare type of cancer,
accounting for 12% of all lymphomas and 0.6% of all new cancer cases,
but overall prognosis is very good. However, treatment options for
those patients who have failed first-line treatment are very few, and
a significant unmet medical need remains in those patients.
GlobalData estimated the HL market in the 7MM was valued at $316m in
2014. The HL market will increase approximately four-fold over the
forecast period, reaching $1.4 billion by 2024 at a CAGR of 16%. This
growth will be driven by label extensions for Adcetris (brentuximab
vedotin), which is poised to enter earlier lines of HL therapy, as
well as the approval and uptake of premium-priced products, such as
the immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda
(pembrolizumab). By the end of the forecast period, GlobalData
expects Adcetris to retain and extend its lead as the HL market
front-runner, with Opdivo and Keytruda making up a significant amount
of the market. GlobalData anticipates that pipeline agents will have
to show an efficacy advantage over currently used and inexpensive
standard of care therapies. The challenge for new entrants in the HL
market is to meet the high unmet need of relapsed or refractory (R/R)
HL patients, reduce the long-term toxic side effects of current
treatments, and improve overall survival.
Highlights
Key Questions Answered
- Over the last forty years, only
one targeted therapy has been approved for the treatment of HL -
Adcetris. The HL space is now filled with excitement because Adcetris
label extensions and approval of the first anti-PD-1 therapies are
expected to change the treatment landscape. What will be the impact
of these newly approved drugs on HL sales?
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/705200
- With the success of
molecular-targeted therapies, including immune checkpoint inhibitors,
across the oncology therapy area, what R&D strategies are being
leveraged by companies to remain competitive in the HL space?
- The survival of R/R HL patients
remains poor, especially for those who fail transplant therapies.
Therefore, there are considerably high unmet needs within this
indication. What are the main unmet needs remaining in this space?
Will the drugs under development fulfil the unmet needs of the HL
market?
Key Findings
- One of the main drivers in the
expansion of the HL market will be the label extensions of Adcetris
in earlier lines of HL therapy, which will include the
post-transplantation consolidation setting, as well as newly
diagnosed advanced stage patients. The premium-priced
anti-PD1-therapies, Opdivo and Keytruda, will also launch and be used
in the treatment of the R/R HL population. These drugs are poised to
partially meet the remaining unmet medical need of these
hard-to-treat patients.
- Another driver of market growth
will be the few players in the HL space; therefore, there is ample
room for new market entrants. A major driver will also be an increase
in HL incidence due to a growing population. This will lead to an
overall increase of the number of drug-treatable HL patients, and
market size.
- Companies are focusing on the
development of therapies targeting the R/R HL population, hoping to
expedite the route to market for their pipeline products, and
improving the complete remission rate and duration of remission of
these patients.
- One of the largest unmet needs
is that of the newly diagnosed advanced stage HL population. Other
unmet needs include the high proportion of patients failing
transplant therapies and the toxicity of second-line treatment
options.
Scope
- Overview of HL, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, disease
management, and current treatment options.
- Top-line HL therapeutics market
revenue from 2014-2024. Average cost of therapy (ACOT) and major
pipeline product sales in this forecast period are included.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, R&D strategies, and clinical trial design for the HL
market.
- Pipeline analysis: comprehensive
data split across different phases, emerging novel trends under
development, synopses of innovative early-stage projects, and
detailed analysis of late-stage pipeline products. An interactive
clinical and commercial analyzer tool is available.
- Analysis of the current and
future market competition in the global HL market. Insightful review
of the key industry drivers, restraints and challenges. Each trend is
independently researched to provide qualitative analysis of its
implications.
Send
An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/705200
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline.
- Develop business strategies by
understanding the trends shaping and driving the global HL market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the global HL market in the
future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analysing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Table of Contents
1 Table of Contents 12
1.1 List of Tables 17
1.2 List of Figures 21
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 23
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology
26
3.1.1 Etiology 26
3.1.2 Pathophysiology 28
3.2 Symptoms 33
3.3 Diagnosis 34
3.4 Clinical Staging and
Prognostic Factors 34
4 Epidemiology 37
4.1 Disease Background 37
4.2 Risk Factors and Comorbidities
38
4.3 Global Trends 39
4.3.1 Incidence 39
4.3.2 Survival Rates for HL - 7MM
42
4.4 Forecast Methodology 43
4.4.1 Sources Used 46
4.4.2 Sources Not Used 47
4.4.3 Forecast Assumptions and
Methods, HL Diagnosed Incident Cases 48
4.4.4 Forecast Assumptions and
Methods, HL Five-Year Diagnosed Prevalent Cases 49
4.4.5 Forecast Assumptions and
Methods, HL Diagnosed Incident Cases, Clinical Stages at Diagnosis 49
4.4.6 Forecast Assumptions and
Methods, HL Diagnosed Incident Cases, Cellular Types 50
4.5 Epidemiological Forecast for
HL (2014-2024) 51
4.5.1 Diagnosed Incident Cases of
HL 51
4.5.2 Age-Specific Diagnosed
Incident Cases of HL 52
4.5.3 Sex-Specific Diagnosed
Incident Cases of HL 54
4.5.4 Age-Standardized Diagnosed
Incidence of HL 56
4.5.5 Diagnosed Incident Cases of
HL by Clinical Stage at Diagnosis 58
4.5.6 Diagnosed Incident Cases of
HL by Cellular Types 59
4.5.7 Five-Year Diagnosed
Prevalent Cases of HL 60
4.6 Discussion 61
4.6.1 Epidemiological Forecast
Insight 61
4.6.2 Limitations of the Analysis
62
4.6.3 Strengths of the Analysis 62
5 Current Treatment Options 64
5.1 Overview 64
5.1.1 Treatment of Classical HL 65
5.1.2 Treatment of NLPHL 68
5.1.3 Treatment of Children and
Pregnant HL Patients 68
5.1.4 Marketed Agents for the
Treatment of HL 69
5.2 Product Profiles 70
5.2.1 Adcetris (brentuximab
vedotin) 70
6 Unmet Needs Assessment and
Opportunity Analysis 89
6.1 Unmet Needs Analysis 89
6.1.1 Overview 89
6.1.2 Low Cure Rate in Newly
Diagnosed Advanced Unfavorable-Stage Patients 90
6.1.3 Only Half of
Relapse/Refractory Patients Are Cured by ASCT 91
6.1.4 Toxic Second-Line
Chemotherapy 92
6.1.5 Long-Term Toxicity
Associated With Radiotherapy 93
6.1.6 Current Treatment Is Less
Effective in Older HL Patients 94
6.1.7 Underuse of Prognostic
Factors for Treatment Planning in the Front-Line and
Relapse/Refractory Settings 95
6.1.8 Prohibitively High Cost of
Therapy 96
6.1.9 Lack of Patients to
Participate in Clinical Trials 97
6.2 Opportunity Analysis 98
6.2.1 Overview 98
6.2.2 Less Toxic and More
Efficacious Front-Line Therapies Will Increase Acceptance for Premium
Price 98
6.2.3 Therapies and Strategies
That Improve Cure Rates in the Relapse/Refractory Setting 100
6.2.4 New Therapies Adapted for
the Treatment of Older HL Patients 102
6.2.5 Pharmacological Therapies
That Can Replace Radiation Therapy 103
6.2.6 Reducing Treatment Cost to
Enhance Overall Treatment Rate and Drug Uptake 104
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment